STOCK TITAN
  1. Home
  2. News
  3. KZR

Kezar Life Sciences - KZR STOCK NEWS

Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.

Kezar Life Sciences (KZR) is a clinical-stage biotechnology company pioneering novel small molecule therapeutics for autoimmune disorders and oncology. This page provides authoritative updates on corporate developments, clinical research, and strategic initiatives essential for informed decision-making.

Access real-time updates on KZR-616 clinical trials, regulatory milestones, and scientific advancements alongside financial disclosures and partnership announcements. Our curated news collection serves investors, researchers, and healthcare professionals seeking comprehensive insights into the company’s progress.

Key coverage areas include immunoproteasome inhibitor developments, trial phase updates, intellectual property news, and collaborative research efforts. All content undergoes rigorous verification to ensure alignment with SEC filings and peer-reviewed publications.

Bookmark this page for streamlined access to KZR’s latest material events. Combine our news monitoring with SEC filings and medical journals for complete due diligence.

News

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) CEO to participate in Cardiorenal Corporate Panel at TD Cowen 44th Annual Health Care Conference. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
-
News

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Rhea-AI Summary
Everest Medicines and Kezar Life Sciences receive approval for Phase 2b PALIZADE trial in China for zetomipzomib in lupus nephritis patients, marking a significant milestone in the development of novel autoimmune disease treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
none
-
News

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) CEO to participate in fireside chat at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences
News

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Kezar Life Sciences, Inc. (Nasdaq: KZR) extends cash runway through strategic restructuring and collaboration with Everest Medicines to develop and commercialize zetomipzomib in Asia. Christopher Kirk, Ph.D., appointed as Chief Executive Officer. Financial results show $218.2 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
earnings
-
News

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Kezar Life Sciences, Inc. (Nasdaq: KZR) has granted a nonqualified stock option to an employee, allowing them to purchase 50,000 shares of common stock at an exercise price of $0.77 per share. The stock option was granted as an inducement award to the individual joining the company. It will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remaining shares vesting monthly thereafter, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Kezar Life Sciences grants employee stock option
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
none
News

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

Rhea-AI Summary
Kezar Life Sciences, Inc. announces strategic realignment to focus on clinical programs, reducing workforce by 41% and extending cash runway to late 2026. Co-Founder Christopher Kirk appointed as CEO. Prioritizing clinical data readouts for zetomipzomib and KZR-261. Exploring strategic partnerships for protein secretion platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
management
-
News

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

Rhea-AI Summary
Kezar Life Sciences partners with Everest Medicines to develop and commercialize zetomipzomib in Greater China, South Korea, and Southeast Asia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
News

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary
Kezar Life Sciences, Inc. (Nasdaq: KZR) will participate in three upcoming investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences
News

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) reported financial results for the second quarter of 2023, with $236.6 million in cash, and provided updates on its clinical trials for zetomipzomib in lupus nephritis and autoimmune hepatitis, as well as the dose escalation study for KZR-261.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.34%
Tags
earnings
Stock KZR logo
Kezar Life Sciences

Nasdaq:KZR

KZR Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

KZR Stock Data

30.39M
6.23M
12%
62%
0.64%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO